• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

12.10 -0.34 (-2.73%)
Delayed Quote Updated: 11:09 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,085
Open 12.51
Bid (Size) 12.10 (5,800)
Ask (Size) 12.37 (100)
Prev. Close 12.44
Today's Range 12.10 - 12.83
52wk Range 8.480 - 16.93
Shares Outstanding 34,422,063
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
October 02, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
September 30, 2026
From MiNK Therapeutics
Via GlobeNewswire

Performance

52-Week Range 28.5% below 52-week high
12.10
8.4852W Low 16.9352W High
1 Week 6.8% below 1-week high
11.711W Low 12.981W High

MiNK Therapeutics, Inc. - Common Stock (INKT) traded between $8.48 and $16.93 over the past 52 weeks and last traded at $12.10, 28.5% below its 52-week high. Over the past week it ranged between $11.71 and $12.98.

Past 12 Months
-0.1%
+4.0%
+4.7%
+5.8%
+8.8%
-20.3%
1W -$0.01
1M +$0.46
3M +$0.54
6M +$0.66
YTD +$0.98
1Y -$3.09

INKT was -20.3% over the past year, +5.8% over six months, +8.8% year to date, -0.1% in the last week.

12 Months vs Market
INKT
-20.3%
DIA
+9.2%
SPY
+15.0%
QQQ
+24.0%
IWM
+14.2%

Over the past 12 months INKT returned -20.3% versus DIA (Dow) +9.2%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.0% and IWM (Russell 2000) +14.2%.

Volume & Liquidity 1.03× 3-mo avg
Today 14,085 3-mo avg 13.6K
1W
34.1K
1M
21.1K
3M
13.6K
6M
26.9K
YTD
112.9K
1Y
90.8K

INKT most recently traded 14,085 shares against a 3-month average daily volume of 13.6K.

More News

Read More
News headline image
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing ↗
May 15, 2026
Via Chartmill
News headline image
MiNK Therapeutics Q2 Earnings Call Highlights ↗
August 13, 2026
Via MarketBeat
Topics Earnings
News headline image
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
August 13, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
August 06, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
August 06, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
June 03, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
May 28, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
May 20, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK (INKT) Q4 2025 Earnings Call Transcript ↗
May 15, 2026
Via The Motley Fool
Topics Earnings
News headline image
MiNK (INKT) Q1 2026 Earnings Call Transcript ↗
May 15, 2026
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Q1 Earnings Call Highlights ↗
May 15, 2026
Via MarketBeat
Topics Earnings
News headline image
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
May 15, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
May 14, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
May 12, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
May 08, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
April 03, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
April 02, 2026
From MiNK Therapeutics
Via GlobeNewswire
These stocks are gapping in today's session ↗
April 01, 2026
Via Chartmill
News headline image
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
April 01, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
March 31, 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
March 17, 2026
From MiNK Therapeutics
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
March 11, 2026
Via Chartmill

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
What is the current price of MiNK Therapeutics, Inc. - Common Stock?
The current price of MiNK Therapeutics, Inc. - Common Stock is 12.10
When was MiNK Therapeutics, Inc. - Common Stock last traded?
The last trade of MiNK Therapeutics, Inc. - Common Stock was at 10/05/26 11:09 AM ET
What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 416.51M
How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
MiNK Therapeutics, Inc. - Common Stock has 417M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap